Serum b-HCG as a biomarker in neuroendocrine tumors: A reconsideration of single-analyte approach

#3977

Introduction: Despite recent advances, neuroendocrine tumors (NETs) remain a challenging topic due to their diverse characteristics and the lack of suitable biomarkers. The shift to an omics-based approach and the utilization of statistical algorithms present an improvement over the traditional single-analyte strategy, albeit with its own drawbacks.

Aim(s): To explore the potential of serum beta-human chorionic gonadotropin (b-hCG) as a biomarker in NETs and to reflect on its role in disease monitoring.

Materials and methods: We measured serum b-HCG concentrations in 40 NETs patients every 3 months over a 48-month period. All patients were diagnosed with non-functioning pancreatic NETs with liver metastases and were treated with somatostatin analogues. We performed a comparative analysis and a repeated measures analysis of b-hCG, considering variables such as grading, liver tumor burden, and treatment response according to RECIST 1.1.

Conference:

Presenting Author: Komarnicki P

Authors: Komarnicki P, Gut P, Musiałkiewicz J, Maciejewski A, Cieślewicz M,

Keywords: pancreatic neoplasms, neuroendocrine tumor, biomarker, chorionic gonadotropin, hcg-beta,